Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Opts For OTC Recall, With J&J/McNeil Lessons Still Fresh

This article was originally published in The Tan Sheet

Executive Summary

After shuttering its Lincoln, Neb., OTC facility, the firm recalls some lots of Bufferin, Excedrin, Gas-X and NoDoz. FDA found a “pattern of problems” when inspecting the plant in 2011, and Novartis’ actions suggest it seeks to avoid the same scrutiny that Johnson & Johnson’s OTC recalls elicited.

You may also be interested in...



Liquid Rolaids Featured In Line’s Re-launch Into Crowded Antacid Market

Less than a year after Sanofi acquired Rolaids from Johnson & Johnson, its Chattem subsidiary reintroduces the antacid brand with tablet and liquid products in varying strengths. The liquid products could capitalize on Maalox and Mylanta missing from retail.

Liquid Rolaids Featured In Line’s Re-launch Into Crowded Antacid Market

Less than a year after Sanofi acquired Rolaids from Johnson & Johnson, its Chattem subsidiary reintroduces the antacid brand with tablet and liquid products in varying strengths. The liquid products could capitalize on Maalox and Mylanta missing from retail.

Bayer Migraine Formula Seeks Market Share Before Excedrin Returns

Bayer Migraine Formula, already in major retailers nationwide, is “a welcome addition to the pain relief aisle for migraine sufferers … affected by the OTC supply issues this year,” the firm says, referring to Novartis’ voluntarily recall of Excedrin.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel